Evidence map›Paper›PMID 25904903›Full record

ArticleFrontiers in microbiology2015

Natural killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice.

Fumiko Obata, Priyanka B Subrahmanyam, Aimee E Vozenilek, Lauren M Hippler, Tynae Jeffers, Methinee Tongsuk, Irina Tiper, Progyaparamita Saha, Dakshina M Jandhyala, Glynis L Kolling and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. [Expression of regulatory T cells and natural killer T cells in peripheral blood of children with Wilms tumor].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2016
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Fumiko ObataDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA ; Department of Molecular Pathology, University of Yamanashi Graduate School of Medicine Chuo, Japan.
Priyanka B SubrahmanyamDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Aimee E VozenilekDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Lauren M HipplerDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Tynae JeffersDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Methinee TongsukDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Irina TiperDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Progyaparamita SahaDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
Dakshina M JandhyalaDepartment of Molecular Biology and Microbiology, Tufts University Boston, MA, USA.
Glynis L KollingDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia Charlottesville, VA, USA.
Olga LatinovicDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA ; Institute of Human Virology, University of Maryland School of Medicine Baltimore, MD, USA.
Tonya J WebbDepartment of Microbiology and Immunology, University of Maryland School of Medicine Baltimore, MD, USA.
University of Maryland, Baltimore · USTufts University · USUniversity of Virginia · USUniversity of Yamanashi · JP

Funding

New therapeutics for Shiga toxin-E. coli disease.U01AI075778 · NIAID · UNIVERSITY OF VIRGINIA · PI OBATA, FUMIKO · 2007 to 2011
$3.9M
aAPC-Mediated NKT cell Modulation to Enhance Cancer ImmunotherapyK01CA131487 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2008 to 2012
$584k
Molecular mechanisms of Shiga toxin action in the mammal central nervous systemR56AI090144 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI OBATA, FUMIKO · 2011 to 2011
$375k
Restoring NKT cell function: a novel immunotherapeutic strategy for Breast CancerR21CA162273 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$367k
Altered cellular bioenergetics influences NKT cell mediated responses to LymphomaR21CA162277 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WEBB, TONYA J. · 2011 to 2012
$359k
NCI NIH HHS K01 CA131487NCI NIH HHS R21 CA162273NCI NIH HHS R21 CA162277NIAID NIH HHS R56 AI090144NIAID NIH HHS U01 AI075778
6 · The paper itself

Abstract

Shiga toxin-producing Escherichia coli (STEC) is a leading cause of childhood renal disease Hemolytic Uremic Syndrome (HUS). The involvement of renal cytokines and chemokines is suspected to play a critical role in disease progression. In current article, we tested the hypothesis that NKT cells are involved in Stx2-induced pathology in vivo. To address this hypothesis we compared Stx2 toxicity in WT and CD1 knockout (KO) mice. In CD1KO mice, which lack natural killer T (NKT) cells, Stx2-induced pathologies such as weight loss, renal failure, and death were delayed. In WT mice, Stx2-specific selective increase in urinary albumin occurs in later time points, and this was also delayed in NKT cell deficient mice. NKT cell-associated cytokines such as IL-2, IL-4, IFN-γ, and IL-17 were detected in kidney lysates of Stx2-injected WT mice with the peak around 36 h after Stx2 injection. In CD1KO, there was a delay in the kinetics, and increases in these cytokines were observed 60 h post Stx2 injection. These data suggest that NKT cells accelerate Stx2-induced pathology in mouse kidneys. To determine the mechanism by which NKT cells promote Stx2-associated disease, in vitro studies were performed using murine renal cells. We found that murine glomerular endothelial cells and podocytes express functional CD1d molecules and can present exogenous antigen to NKT cells. Moreover, we observed the direct interaction between Stx2 and the receptor Gb3 on the surface of mouse renal cells by 3D STORM-TIRF which provides single molecule imaging. Collectively, these data suggest that Stx2 binds to Gb3 on renal cells and leads to aberrant CD1d-mediated NKT cell activation. Therefore, strategies targeting NKT cells could have a significant impact on Stx2-associated renal pathology in STEC disease.

Indexed as

cytokinesEscherichia colihemolytic uremic syndromemouse modelsnatural killer T cellShiga toxinsingle molecule imagingSTORM-TIRF

Identifiers

PMID25904903
PMCPMC4389548
OpenAlexW2009869492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.